Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | GHSR | Q92847 | 2/20 | 0.47 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29679650 | 0.93 | ERAP2 (0.55) | MMP2ERAP2LNPEPOPRK1 | |
| SCHEMBL30099540 | 0.92 | MMP2 (0.56) | MMP2ERAP2LNPEPOPRK1CTSL | |
| SCHEMBL20964469 | 0.91 | CTSL (0.49) | MMP2OPRK1CTSLGHSRKISS1R | |
| SCHEMBL6431108 | 0.91 | MMP2 (0.56) | MMP2ERAP2LNPEPOPRK1CTSL | |
| SCHEMBL30688828 | 0.91 | MMP2 (0.56) | MMP2ERAP2LNPEPOPRK1CTSL | |
| SCHEMBL28323436 | 0.91 | MMP2 (0.56) | MMP2ERAP2LNPEPOPRK1CTSL | |
| SCHEMBL20964474 | 0.90 | MMP2 (0.50) | MMP2OPRK1CTSLGHSR | |
| SCHEMBL29641053 | 0.89 | MMP2 (0.53) | MMP2ERAP2LNPEPOPRK1CTSL | |
| SCHEMBL29408578 | 0.88 | ERAP2 (0.53) | MMP2ERAP2LNPEPOPRK1 | |
| SCHEMBL29763133 | 0.88 | BACE1 (0.53) | ERAP2LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220526-B2 | Neuropeptide S receptor (NPSR) agonists | RESEARCH TRIANGLE INSTITUTE (US) | 2022-01-11 | — | — | US | disclosed |
| US-20190127419-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | RESEARCH TRIANGLE INSTITUTE | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127419-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | NPSR1, GRPR, NPBWR1 | MMP2 2707/4885ERAP2 1105/4885LNPEP 373/4885 |
| US-11220526-B2 | Neuropeptide S receptor (NPSR) agonists | NPSR1, GRPR, NPBWR1 | MMP2 2707/4885ERAP2 1105/4885LNPEP 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.